|
45 documents found matching vioxx NOT (cs:cona* OR cs:humeston* OR cs:herman* OR cs:ernst* OR cs:neuron*).
|
|
of 5
Prev
Next
|
|
|
|
Showing 1-10 of 45 documents
|
1.
Offensive Positioning for Vioxx
|
Document Date:
|
20000728
|
|
Corporate Author:
|
Merck & Co., Inc
|
|
Search Terms in Context:
|
0 MERCK
TO: All RBG VPs and Senior Business Directors
MEMO
FROM: MIT for Vioxx®
SUBJECT: Offensive Positioning for Vioxx® . DATE: 07128/00 -
In order to win the on-going COXIB battle, many of you agree our sales force needs to STOP
defending Vioxx® against the outrageous claims from our competitors, and START offensively
selling the care benefit of this product...EFFICACY.
It is evident
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/qjb00a10
|
|
| |
2.
Bulletin for Vioxx: New Resource: Cardiovascular Card
|
Document Date:
|
00000000
|
|
Corporate Author:
|
Merck & Co., Inc
|
|
Search Terms in Context:
|
No. COX 00-028
Apr 28, 2000
Bulletin for VIOXX®:
NEW RESOURCE: Cardiovascular Card
TO:
Aq Field Personnel with Responsibility for VIOXX®
Background
ACTION REQUIRED
The presentation of information regarding the VIGOR and CLASS trials has led to some
misunderstanding in the field, as well as with physicians, regarding the cardiovascular effects of
VIOXX
To ensure that you are well prepared
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/ljb00a10
|
|
| |
3.
Bulletin for Vioxx: Action Required: Response to the New York Times Article
|
Document Date:
|
20010523
|
|
Corporate Author:
|
Merck & Co., Inc
|
|
Search Terms in Context:
|
No. COX 01-03C
May 23, 2001
Bulletin for VIOXXm:
Action Required: Response to New York Times Article
TO:
All Field Representations with Responsibility for VIOXX Action Required
All Hospital Representatives . Action Required
A & A Specialty Representatives Action Required
A& A HSAs Action Required
Urology Representatives Action Required
Neurology Representatives Action Required
Managed Care NAEs
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/uib00a10
|
|
| |
4.
Bulletin for Vioxx: Action Required: Observational Analysis by Graham et. al.
|
Document Date:
|
20040826
|
|
Corporate Author:
|
Merck & Co., Inc
|
|
Search Terms in Context:
|
No. COX 04-063
Aug 26, 2004
BULLETIN FOR VIOXX:
Action Reaufred: ObservaBonal Analysis by Graham ett al.
TO:
Primary Care Representatives with Responsibility for VIOXX
A & A Specialty Representatives . Hospital Representatives with Responsibility for V/OXX
A&AHSAs NeurologyNrotogy Specialty Representatives
HIV Specialty Representatives Cardiovascular Specialty Representatives
Managed Care NAEs
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/wib00a10
|
|
| |
5.
Hospital Strategy Simulation: Roleplayer's Guide, September, 2000
|
Document Date:
|
20000900
|
|
Corporate Author:
|
Merck & Co., Inc
|
|
Search Terms in Context:
|
and Emergency
Medicine. To simplify the plot for the roleptayers, there are Pharmacy
Customer Profile cards for representatives for Aggraslat and
Pharmncy Customer Profile cards for representatives for Vioxx.
Similarly, there are Emergency Medicine Customer Profile cards for
representatives for Aggrastat and EmerRency Medicine Customer
Profele cards for representatives fr Vioxx.
Note that for some
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/zib00a10
|
|
| |
6.
Application Number: 21-042/S-007, S-008, S-010, S-012, S-013, S-014 and 21-052/S-004, S-005, S-006, S-007, S-008, S-009 - Final Printed Labeling
|
Document Date:
|
20020400
|
|
Corporate Author:
|
Center for Drug Evaluation and Research
|
|
Search Terms in Context:
|
j
CENTER FOR DRUG EVALUATION AND RESEARCH
APPLICATION NUMBER: 21-042/S-007, S-008, S-010,
S-012, S-013, S-014 and 21-052/S-004, S-005, S-006,~ S-
007, S-008, S-009
FINAL PRINTED LABELING
. rmA 21 o421S007,S -0o3, s-o1o, s-0t2, s-ot3, 3-014
NDA 21-052/5-004, 5-005, 5-006, 5-007, S-008, S-009
Yagc 4
VtOXX®
(rofecoxib tablets and oral suspension)
. DESCRIPTION
VIOXX' (rofecoxib) is described
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/sjb00a10
|
|
| |
7.
MVX for Vioxx: Valdecoxib Approval
|
Document Date:
|
20011120
|
|
Author:
|
Jerman, Jo
|
|
Corporate Author:
|
Merck & Co., Inc
|
|
Search Terms in Context:
|
MVX for Vloxx®
Jo Jerman to USHH
November 20, 2001
Valdecoxlb approval
Hi ya111 Jo Jerman here with an MVX going out over the airwaves to all Representatives who
have responsibility for VIOXX. I apologize for sending you another message especially this close
to the holidays, but this information is too important for me to hold.
I am sending this message to let you know that Friday, Pharmacla
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/ikb00a10
|
|
| |
8.
Bulletin for Vioxx: New Obstacle Response
|
Document Date:
|
00000000
|
|
Corporate Author:
|
Merck & Co., Inc
|
|
Search Terms in Context:
|
No. COX 00-029
May 01, 2000
Bulletin for VIOXXm:
New Obstacle Response
TO:,
AII field personnel with responsibility for VIOXXm Action Required
PURPOSE:
To provide you with a new obstacle response relating to the press release and
Seade/Pf¢er's promotion that VIOXX has an increased incidence of heart attacks
compared to Celebrex, based on the VIOXX GI Outcomes Trial compared to Celebrex
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/pjb00a10
|
|
| |
9.
Cardiovascular System: Clinical Profile in Osteoarthritis Studies
|
Document Date:
|
00000000
|
|
Corporate Author:
|
Merck & Co., Inc
|
|
Search Terms in Context:
|
(MI)
Congestive heart failure (CHF) 1%
*Mean age: 63 years (range: 39-93). Gender: 70%female, 30% male.
VIOXX is indicated for:
Relief of the signs and symptoms of osteoarthritis (OA).
The management of acute pain in adults (see CLINICAL STUDIES).
Treatment of primary dysmenorrhea.
Selected safety information
VIOXX is contraindicated in patients with known hypersensitivrty to rofecoxib
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/njb00a10
|
|
| |
10.
MVX for Vioxx: ""BEXTRA Follow-up and CV Outcomes Trial""
|
Document Date:
|
20011211
|
|
Author:
|
Jerman, Jo
|
|
Corporate Author:
|
Merck & Co., Inc
|
|
Search Terms in Context:
|
FINAL
MVX for V{OXX°
Field Sales-lSHH
Jo Jarrnan
December 11, 2001
`BEXTRA follow-up and CV Outcomes TriaP
Hey guys-Jo Jerman here with a voicemail going out over the airwaves to all Representatives with
responsibility for VIOXX. I hope you all had a fantastic holiday and a chance to re-charge
yourselves for the last stretch of the year.
Before I jump into an update on our latest competitor
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/jkb00a10
|
|
| |
|
Prev
Next
|
